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Liver Group, Institute of Cellular Medicine, Newcastle University, United KingdomNon-alcoholic fatty liver disease (NAFLD) is now the commonest liver disorder in the developed world aﬀecting up to a
third of individuals. It is closely associated with features of the metabolic syndrome, particularly obesity and diabetes. It
can progress to cirrhosis, hepatocellular carcinoma and liver failure and is an increasing indication for transplantation.
Dietary and genetic factors determine susceptibility to NAFLD and its progression. NAFLD may also be involved in
the pathogenesis of cardiovascular disease. Most patients present with incidentally found abnormal liver blood tests. Diag-
nosis is usually one of exclusion. Liver biopsy is required for disease staging, but new imaging modalities and biomarkers
are emerging which may eventually fulﬁl this role. There is, as yet no ﬁrm evidence-based treatment for NAFLD. Therapy
is currently directed at treating components of the metabolic syndrome which may also be beneﬁcial for the liver. The
recent elucidation of the mechanisms leading to progressive disease suggests a variety of novel targets worthy of testing
in animal models of NAFLD and subsequently in pilot studies in humans.
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Non-alcoholic fatty liver disease (NAFLD) is increas-
ingly diagnosed worldwide and considered to be the
commonest liver disorder in Western countries. It com-
prises a disease spectrum which includes variable
degrees of simple steatosis (fatty liver), non-alcoholic
steatohepatitis (NASH) and cirrhosis. Simple steatosis
is benign, whereas steatohepatitis (NASH) is character-
ised by hepatocyte injury, inﬂammation and ﬁbrosis
which can lead to cirrhosis, liver failure and hepatocellu-
lar carcinoma (HCC).
NAFLD is strongly associated with obesity, insulin
resistance, hypertension and dyslipidaemia and is now
regarded as the liver manifestation of the metabolic syn-
drome. Rapid spread of the obesity ‘pandemic’ in adults
and children, coupled with the realisation that the out-
comes of obesity-related liver disease are not entirely
benign, has led to rapid growth in clinical and basic
studies in NAFLD. This review will concentrate on an
update of clinical aspects of this increasingly important
disease.Published by Elsevier B.V. All rights reserved.
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NAFLD is often an asymptomatic illness in which the
liver blood tests may be completely normal. This has
made studies on prevalence extremely diﬃcult with most
relying on ultrasound which is known to be sensitive only
whenmore than a third of the liver is aﬀected by steatosis.
With this proviso the prevalence ofNAFLDappears to be
around 20–30% inWestern adults [1,2] and 15% inAsians
[3]. Due to the lack of prospective studies, the true inci-
dence of NAFLD is not well deﬁned, although from the
information available, it appears to be low [4]. Since liver
biopsy is the onlymethod of accurately diagnosing steato-
hepatitis, incidence/prevalence studies of NASH are rare.
According to available data, NASH is much rarer than
NAFLD, aﬀecting 2–3% of the general population [5].
NAFLD and NASH are strongly associated with the
presence and severity of obesity. Studies in severely obese
patients (BMI > 35 kg/m2) undergoing bariatric surgery
have reported prevalences of NAFLD and NASH of
91% and 37%, respectively [6] while a post-mortem study
reported NASH to be present in 3% of non-obese, 19% of
obese and 50% of a morbidly obese individuals [7]. A
recent novel observational study in NAFLD patients
has demonstrated that while central obesity correlates
with the severity of inﬂammation, dorsocervical lipohy-
pertrophy correlates with hepatocyte injury, inﬂamma-
tion and ﬁbrosis [8]. Type 2 diabetes mellitus (T2DM) is
the other major association of NAFLDwith a prevalence
of 70% recently reported from an ultrasound survey of
almost 3000 unselected Italian T2DM patients [9,10].
Even in the absence of obesity andT2DM,NAFLD is clo-
sely associated with other features of the metabolic syn-
drome, with one study of non-diabetics with NAFLD
reporting that 18% of normal weight patients and 67%
of obese fulﬁlled criteria for the metabolic syndrome [11].
There are no accurate data regarding temporal
changes in the prevalence of NAFLD, however, the ris-
ing prevalence of obesity, diabetes and the metabolic
syndrome seems likely to be reﬂected in an increasing
prevalence of NAFLD. This trend is of particular con-
cern in the paediatric population where the reported
increase in obesity will undoubtedly result in a higher
incidence and prevalence of paediatric and adult
NAFLD in the future. To date, studies in children have
reported a prevalence of NAFLD of 3% in the general
paediatric population and 53% in obese children
[12,13]. Reports of toddlers with NAFLD and primary
school children with NAFLD-related cirrhosis are
clearly a cause for alarm [14].CirrhosisLiver
Death/
OLTx 25-50%
25%
Fig. 1. Natural history of NAFLD over 8–13 years. HCC, hepatocel-
lular carcinoma; OLTx, liver transplantation. Source Refs. [15,16].3. Natural history of NAFLD
In marked contrast to alcoholic steatohepatitis, the
short-termprognosis ofNAFLD is good. The largest pro-spective histological study of the natural history of
NAFLD, with a mean follow-up of 13 years, has recently
been published [15]. Data from this and other studies sug-
gest that the long-term hepatic prognosis of patients with
NAFLD depends on the histological stage of disease at
presentation [16] (Fig. 1). Among patientswith simple ste-
atosis 12–40%will developNASHwith early ﬁbrosis after
8–13 years. For patients presenting withNASH and early
ﬁbrosis, around 15% will develop cirrhosis and/or
evidence of hepatic decompensation over the same time
period, increasing to 25% of patients with advanced pre-
cirrhotic ﬁbrosis at baseline. In the most recent study,
weight gain and the presence of portal tract ﬁbrosis on
index biopsy were the only signiﬁcant predictors of ﬁbro-
sis progression [15]. About 7% of subjects with compen-
sated cirrhosis associated with NAFLD will develop a
hepatocellular carcinoma (HCC) within 10 years, while
50% will require a transplant or die from a liver-related
cause [17]. The risk of HCC in NAFLD-related cirrhosis
is comparable to that in cirrhosis associated with alcohol
or hepatitis C [18]. This may partly explain the recently
reported associations of HCC with high BMI and
T2DM [19]. Liver transplantation is increasingly avail-
able to those with chronic liver failure and about 10–
12% of liver transplants in the United States are for
NAFLD cirrhosis [20]. Unfortunately, the condition
can recur in transplanted organs. The overall survival of
patients with NAFLD is less than that of an age- and
sex-matched population, with liver disease the 3rd leading
cause of death in NAFLD patients compared to the 13th
leading cause in a general population [21].4. Susceptibility
While the vast majority of individuals with obesity,
insulin resistance and the metabolic syndrome will have
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tis, ﬁbrosis and cirrhosis. Potential environmental deter-
minants of NAFLD are dietary factors and small bowel
bacterial overgrowth [22]. Recent studies have shown
that diets high in saturated fat, soft drinks and meat
and low in anti-oxidants and omega 3-containing ﬁsh
are associated with an increased risk of NAFLD/NASH
[23,24]. With respect to alcohol intake, while there is no
doubt that obesity increases risk of cirrhosis in heavy
drinkers [25] emerging evidence suggests that ‘‘sensible”
light alcohol intake may be protective versus NAFLD/
NASH [26,27], an eﬀect that appears likely to be due
to the beneﬁcial eﬀect of light alcohol intake on insulin
sensitivity. Family studies and inter-ethnic variations in
susceptibility suggest that genetic factors may be impor-
tant in determining disease risk. Although no genetic
associations with advanced NAFLD have been repli-
cated in large studies, preliminary data suggest that
polymorphisms in the genes encoding microsomal tri-
glyceride transfer protein, phosphatidylethanolamine
transferase, superoxide dismutase 2, the CD14 endo-
toxin receptor, TNFa, TGFb and angiotensinogen
may be associated with an increased risk of steatohepa-
titis and/or ﬁbrosis [28]. With the advent of high-
throughput gene analyses and the reduced cost of whole
genome wide scans it seems likely that genes contribut-
ing to inherited susceptibility to this common disease
will be identiﬁed in the near future.5. Disease associations with NAFLD
5.1. Cardiovascular disease
Given the close association between NAFLD and
classical cardiovascular risk factors it is perhaps not sur-
prising that, when compared to controls, patients with
NAFLD have a higher prevalence of atherosclerosis,
as shown by increased carotid wall intimal thickness,
increased numbers of atherosclerotic plaques and
increased plasma markers of endothelial dysfunction
[9,29,30]. This association also extends to children with
the prevalence of coronary and aortic atheroma higher
in children with fatty liver compared to controls in an
autopsy-based report [31]. Consistent with these obser-
vations two natural history studies have reported that
the increased age-related mortality observed in patients
with NAFLD is attributable to cardiovascular as well
as liver-related deaths [15,17]. Although an indirect
association between NAFLD and cardiovascular disease
is expected, a growing body of evidence supports a
direct role for NAFLD in the pathogenesis of atheroma-
tous cardiovascular disease. A recent study of unselected
patients with T2DM reported that the prevalence of car-
diovascular, cerebrovascular and peripheral vascular
disease was signiﬁcantly greater in those with NAFLDthan in those without independent of the individual
components of the metabolic syndrome [10]. A similar
ﬁnding has been observed for microvascular diseases,
nephropathy and retinopathy [32]. The mechanism of
any direct eﬀect of NAFLD on cardiovascular risk
remains unclear; possibilities include the release of ath-
erogenic inﬂammatory cytokines and pro-coagulant fac-
tors from the steatotic liver [33].
5.2. Polycystic ovary syndrome (PCOS)
As with the association between NAFLD and the
metabolic syndrome, the now well-established associa-
tion between NAFLD and the PCOS seems likely to
be indirect as a result of both conditions being charac-
terised by insulin resistance. Up to 30% of females with
PCOS have elevated alanine transaminase (ALT) levels
[34] and a NAFLD prevalence of 42% has been reported
in a series of PCOS patients with a mean age of 25 years
[35]. More recently, advanced ﬁbrotic liver disease has
been reported in patients with PCOS [36] suggesting that
women with this syndrome require careful hepatic
evaluation.
5.3. Obstructive sleep apnoea (OSA)
Chronic intermittent hypoxia, as seen in obstructive
sleep apnoea (OSA), has been associated with cardiovas-
cular disease, the metabolic syndrome and insulin resis-
tance [37]. As might be expected, therefore, a proportion
of patients with OSA have elevated liver enzymes and
histological features of NASH independent of body
weight [38]. The severity of histology and the associated
insulin resistance both correlate with the severity of
OSA, strongly implicating insulin resistance as the path-
ogenic mechanism linking OSA to NASH although not
entirely excluding a role for hypoxic liver injury. As with
PCOS, this and other similar reports suggest that
patients with OSA require hepatic evaluation, and that
the diagnosis of OSA should be considered in NAFLD
patients reporting daytime somnolence, sleep distur-
bances or any other symptoms suggesting a diagnosis
of OSA.6. Clinical features
NAFLD is a largely asymptomatic condition that
may reach an advanced stage before it is suspected or
diagnosed. Symptoms such as right upper quadrant dis-
comfort, fatigue and lethargy have been reported in up
to 50% of patients but are uncommon modes of presen-
tation. Most patients with NAFLD are diagnosed after
they are found to have hepatomegaly, or more com-
monly, unexplained abnormalities of liver blood tests
performed as part of routine health checks or during
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commonest cause of incidental abnormal liver blood
tests accounting for between 60% and 90% of such cases
[39,40]. Importantly, the vast majority (around 80%) of
patients with NAFLD have normal liver blood tests [2]
and there is no diﬀerence in histological severity between
those with and without abnormal tests [41]. Accord-
ingly, NAFLD should be suspected and sought in all
patients with established risk factors, including PCOS
and OSA, regardless of liver blood tests. The history
should concentrate on determining the presence/absence
of conditions commonly associated with ‘‘primary”
NAFLD – metabolic syndrome components, cardiovas-
cular disease and OSA – and on excluding alternative
causes of steatosis including excessive alcohol intake,
previous abdominal surgery (leading to bacterial over-
growth) and drugs causing NAFLD such as amiodarone
and tamoxifen. On examination, most patients are cen-
trally obese and dorsocervical lipohypertrophy (a ‘‘buf-
falo hump”) appears to be a particular feature of the fat
distribution in patients with advanced NAFLD [8]. Fea-
tures of PCOS (hyperandrogenism) should be sought in
young women with suspected NAFLD [35] and clinical
evidence of lipodystrophy should be sought in young,
non-obese patients in view of its association with
NAFLD [42].7. Investigation
In the absence of advanced disease routine liver blood
tests are either normal or typically show mild elevations
of transaminases, alkaline phosphatase and gamma
glutamyl transpeptidase (GGT) 1.5–3  the upper limit
of normal. The ALT/AST ratio is greater than 1 unless
there is advanced ﬁbrotic NAFLD or the patient is a
covert heavy drinker. Other blood tests are aimed at
detecting associated conditions, such as dyslipidaemia,
and excluding alternative causes of abnormal liver blood
tests. Regarding lipids, it is worth measuring serum lev-
els of apolipoprotein B (Apo-B) in patients either with
no obvious risk factors for NAFLD or with low levels
of LDL and HDL cholesterol, looking for evidence of
hypobetalipoproteinemia a rare, familial cause of
NAFLD [43]. Serum ferritin is often raised in NAFLD
patients [44] and has been associated with advanced
ﬁbrosis [45]. HFE genotyping should be carried out
when hyperferritemia is accompanied by raised transfer-
rin saturation. Autoantibodies associated with autoim-
mune hepatitis (AIH), including ANA and SMA, are
often present at low titres in patients with NAFLD
and have been associated with more advanced disease
in some, but not all, studies [46,47]. Around 1 in 10 of
these patients have histological features of autoimmune
hepatitis on biopsy and fulﬁl diagnostic criteria for
probable/deﬁnite AIH [46]. Currently available imagingmodalities including ultrasound, CT and routine MR
imaging are all excellent at detecting steatosis (once
more than around a third of the liver is aﬀected) but
none can reliably detect NASH or ﬁbrosis [48]. Newer
imaging techniques including proton magnetic reso-
nance spectroscopy [49] and transient elastography [50]
show promise but require further study prior to routine
use for disease staging.
7.1. The role of liver biopsy
Undoubtedly the most important and controversial
issue to consider in the investigation of patients with
suspected NAFLD is whether or not to perform a liver
biopsy. For diagnosis, biopsy is not required in a ‘‘typ-
ical” patient with abnormal liver blood tests, classical
risk factors for NAFLD (obesity, T2DM, dyslipidemia)
and an ultrasound showing steatosis, however, a high
ferritin with HFE mutations, positive autoantibodies
(ANA, SMA) or the use of medications associated with
drug-induced liver injury all may justify a biopsy to
exclude alternative/additional diagnoses. The main indi-
cation to perform a biopsy is, however, the accurate
staging of the disease since (a) diﬀerent stages have dif-
ferent prognoses and therefore require diﬀerent manage-
ment strategies, and (b) no currently available imaging
techniques can perform this role [48].
7.2. Non-invasive markers for staging NAFLD
The current reliance on liver biopsy for disease stag-
ing has prompted many studies aimed at deﬁning clinical
or laboratory-based variables capable of acting as surro-
gate markers of disease stage [51]. Various clinical and
laboratory markers have been shown to be associated
with advanced ﬁbrosis (bridging ﬁbrosis or cirrhosis)
in patients with NAFLD, notably advanced age
(>45 years), BMI > 30 kg/m2, T2DM (or raised fasting
blood glucose), the severity of OSA [38] an AST:ALT
ratio greater than 1, hyperferritinemia [45] and positive
autoantibodies [46]. At present, it would therefore seem
reasonable to restrict liver biopsy to patients with at
least some, if not all, of these risk factors. Some of these
markers (age, BMI, T2DM, AST/ALT ratio) have
recently been combined together with platelet count
and serum albumin concentration, into a NAFLD ﬁbro-
sis ‘‘score” that accurately predicts the presence or
absence of advanced ﬁbrosis in the majority of patients
with NAFLD [52]. This score has recently been com-
bined with the European Liver Fibrosis (ELF) panel
of serum ﬁbrosis markers [53] and shown to have an
accuracy of over 90% in diﬀerentiating diﬀerent ﬁbrosis
stages in NAFLD [54]. With respect to the non-invasive
diagnosis of NASH rather than ﬁbrosis stage, serum lev-
els of a caspase cleavage product of the hepatocyte pro-
tein cytokeratin-18 (a putative marker of hepatocyte
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dict the presence of NASH in a small pilot study [55].
Clearly this and other tests and scoring systems require
further validation before they can be used in routine
clinical practice but they do appear, at last, to oﬀer real
potential to replace the need for liver biopsy in the
majority of patients with NAFLD.8. Overall management strategy for NAFLD
Almost no large randomised controlled trials (RCTs)
have been published on which to establish evidence-
based treatment recommendations for NAFLD.
Accordingly, current management strategies are directed
at treating, where present, the individual components of
the metabolic syndrome since this will reduce the risk of
cardiovascular disease and may also be beneﬁcial for the
liver. Alcohol intake should not exceed ‘‘sensible” limits,
but there is no need to advise complete abstinence as an
emerging body of data suggest that light to moderate
intake may actually reduce the risk of NAFLD [25,26].
In view of their largely benign prognosis these strategies
are all that it is required for patients with simple steato-
sis who can be managed by general or primary-care phy-
sicians with no requirement for formal hepatological
follow-up. In contrast, patients with more advanced
NAFLD require long-term follow-up by hepatologists
in light of their increased propensity for disease progres-
sion and the resulting need for surveillance for complica-
tions including esophageal varices and HCC. These
patients will also be candidates either for emerging ‘‘sec-
ond-line” therapies currently being evaluated in large
RCTs or for entry into these trials. The rationale for
NAFLD therapies is based on a growing understanding
of disease pathogenesis with a particular focus on reduc-
ing insulin resistance, hepatic free fatty acid (FFA) lev-
els, oxidative, endoplasmic reticulum and cytokine-
mediated stress and inﬂuencing the balance and eﬀects
of proﬁbrotic, pro-inﬂammatory and anti-ﬁbrotic, anti-
inﬂammatory adipokines released from adipose tissue
[56]. Current and emerging therapies for NAFLD can
be divided into those directed at the metabolic syndrome
components with potential liver eﬀects and those direc-
ted primarily at the liver.9. Treatments directed at components of the metabolic
syndrome
9.1. Obesity
Obesity is a rational target for NAFLD therapy since
weight loss should reduce many of the putative mediators
of liver injury including insulin resistance, hepatic FFA
supply and pro-inﬂammatory, proﬁbrotic adipokines.9.1.1. Diet and exercise
Several small, largely uncontrolled, studies have
shown an improvement in either ALT or steatosis fol-
lowing diet (with or without exercise)-induced weight
loss. There is very little evidence that necroinﬂammation
or ﬁbrosis can be improved by weight loss alone
although a few small case series have shown some
improvement in these parameters with drastic weight
loss (reviewed in [57]). To date, almost all studies of
diet-induced weight loss have employed simple calorie
restriction, with very few attempting to manipulate spe-
ciﬁc dietary components. This area seems worthy of
study, since intake of both saturated fat and ﬁbre are
known to inﬂuence insulin resistance and diets high in
saturated fat, soft drinks and meat and low in omega
3-containing ﬁsh appear to be associated with both
NAFLD and NASH [23]. Dietary fat intake has also
been shown to correlate with liver fat content and insu-
lin resistance in short-term studies of obese, non-dia-
betic women – independently of changes in total-body,
subcutaneous or abdominal fat [58]. The value of exer-
cise in achieving and maintaining weight loss and
improving insulin resistance is well established and thus
far the only controlled study of weight loss that has
reported histological improvement (steatosis) combined
calorie restriction with increased exercise [59].
9.1.2. Pharmacological anti-obesity agents
Encouraging improvements in liver histology have
been reported from pilot studies of the intestinal lipase
inhibitor orlistat in patients with NASH [60,61], how-
ever there is no evidence as yet that this improvement
is over and above what would be expected from the
resulting weight loss. Nonetheless, data from currently
ongoing large RCTs of orlistat are awaited with interest.
The cannabinoid receptor 1 (CB1) antagonist rimona-
bant has been shown to be eﬀective in reducing weight
and waist circumference, with improvements in several
metabolic parameters including insulin resistance [62].
Its eﬀects on the liver in patients with NAFLD are, as
yet, unknown however, animal data demonstrating that
CB1blockade is both anti-steatotic [63] and anti-ﬁbrotic
[64] provide strong rationale for forthcoming clinical tri-
als of drugs directed at the CB1 receptor in NAFLD.
9.1.3. Bariatric surgery
Various surgical procedures are currently in use for
the treatment of obesity. Biliopancreatic diversion
appears to carry a signiﬁcant risk of liver failure and
worsening ﬁbrosis, and should therefore be avoided in
patients with NAFLD, however, more encouraging
results have been reported for gastric bypass and gastric
banding surgery [65,66]. To date, all studies have shown
improvements in metabolic parameters and steatosis
with some, but not all, reporting improvements in necr-
oinﬂammation and ﬁbrosis [65].
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Evidence that insulin resistance may contribute to
both inﬂammation and ﬁbrosis in NAFLD has led to
several pilot studies of metformin and other insulin-
sensitizing agents in patients with NAFLD with and
without diabetes. There is as yet no direct evidence that
hyperinsulinaemia per se adversely aﬀects the liver,
however, evidence from animal studies that insulin is
a direct cause of both hepatic steatosis and ﬁbrosis
[67] might suggest that insulin or sulphonylureas
should be avoided if possible. It is of interest, there-
fore, that a recent pilot study in patients with T2DM
has shown that long-term high dose insulin therapy
results in a reduction of transaminases and hepatic ste-
atosis presumably reﬂecting the beneﬁcial eﬀects of
insulin on blood glucose and adipose tissue lipolysis
[68]. Whether or not long-term insulin therapy
increases ﬁbrosis in patients with NAFLD is, however,
as yet unknown.
9.2.1. Metformin
Pilot studies of metformin in diabetic and non-dia-
betic patients with NAFLD have shown inconsistent
eﬀects on liver blood tests and steatosis (determined by
MRI or MR proton spectroscopy). However, the largest
RCT to date, in non-diabetic NAFLD patients, has
been more encouraging. In this 12-month, randomised
open-label trial, metformin treatment (2 g/day) was
associated with signiﬁcantly higher rates of normalised
aminotransferase levels and with signiﬁcant decreases
in liver fat, necroinﬂammation and ﬁbrosis, compared
with either vitamin E treatment or a weight-reducing
diet treated patients [69]. The low number of patients
who agreed to a second biopsy does, however, limit
the strength of the conclusions that can be drawn from
this study.
9.2.2. Thiazolidinediones (TZDs)
TZDs act as agonists for the peroxisome proliferator-
activated receptor c (PPARc). They improve insulin sen-
sitivity, at least in part, via anti-steatotic eﬀects in the
liver and muscle which may in turn result from an
increase in the secretion of the anti-inﬂammatory, anti-
ﬁbrotic adipokine, adiponectin by adipocytes. More-
over, their potential as a therapy for NAFLD is further
increased by evidence from animal models that they may
also exert direct anti-ﬁbrotic eﬀects in the liver [70]. Pilot
studies of the second-generation TZDs, pioglitazone and
rosiglitazone, have consistently reported encouraging
improvements in insulin sensitivity, liver blood tests
and liver histology and several large RCTs are currently
in progress. The ﬁrst placebo-controlled RCT of pioglit-
azone in the treatment of patients with NASH has
recently reported signiﬁcant improvements in steatosis,
inﬂammation and ballooning necrosis associated witha non-signiﬁcant decrease in ﬁbrosis [71]. A note of cau-
tion over the use of TZDs in the treatment of NASH has
arisen recently as a result of several meta-analyses of tri-
als of TZDs in T2DM patients that have consistently
shown that rosiglitazone increases the incidence of myo-
cardial infarction and heart failure [72]. The risk of heart
failure is also increased by pioglitazone but it is associ-
ated with a lower risk of myocardial infarction and
stroke compared to placebo-treated patients [73]. This
is reassuring since a recent study suggests that pioglitaz-
one treatment for NASH has to be continued long-term
since stopping it led to a worsening of steatosis and
inﬂammation [74].
9.3. Dyslipidaemia
Hypertriglyceridaemia aﬀects 20–80% of patients
with NAFLD. As with anti-obesity and insulin-sensi-
tising drugs, there are sound scientiﬁc reasons to sup-
port the use of ﬁbrates – the conventional triglyceride-
lowering agents – in patients with NAFLD. Fibrates
are agonists for the PPARa receptor, a transcription
factor that up-regulates the transcription of genes
encoding various proteins that would be expected to
reduce hepatic FFA levels and also exerts anti-inﬂam-
matory eﬀects. As with many other potential therapies
for NAFLD, studies of PPARa agonists in animal
models of NASH have been encouraging [75], how-
ever, the only controlled study in patients with histo-
logical follow-up reported that one year of cloﬁbrate
had no eﬀect on liver biochemistry or histology [76].
There is less rationale for using HMG CoA reductase
inhibitors (statins) to treat NAFLD, however, they
can be safely prescribed for ‘‘conventional” indica-
tions, including T2DM and high cardiovascular risk.
Importantly, there is no evidence that patients with
pre-existing NAFLD are at increased risk of statin-
induced idiosyncratic hepatotoxicity, or that statins
are associated with a higher frequency of hepatic ste-
atosis or serum ALT abnormalities in these subjects
[77].
9.4. Hypertension
No RCTs have speciﬁcally examined the eﬀect of dif-
ferent anti-hypertensive agents on the liver in hyperten-
sive patients with NAFLD. However, a growing body of
evidence from animal models of hepatic ﬁbrosis and
NASH suggests that therapy directed at the renin–
angiotensin system and a-blockers may be beneﬁcial
for the liver [78,79]. As yet only one pilot study has
examined the use of angiotensin II receptor blockade
in patients with NASH and showed a reduction in serum
markers of ﬁbrosis [80]. Newer angiotensin II receptor
blockers with insulin sensitising eﬀects seem worthy of
study in NAFLD [81].
S110 N.M.W. de Alwis, C.P. Day / Journal of Hepatology 48 (2008) S104–S11210. Treatments directed at the liver
An increased understanding of the mechanisms of
progressive liver damage in NAFLD has stimulated
the search for therapies speciﬁcally targeting the liver
rather than at the individual components of the meta-
bolic syndrome that may have beneﬁcial eﬀects.
10.1. Anti-oxidants
Several encouraging pilot studies of various agents
indicate potential beneﬁcial eﬀects which may be related
to their anti-oxidant eﬀects. These include probucol [82],
betaine [83], iron depeletion through venesection [84]
and vitamin E [85]. However, a recent RCT of vitamin
E combined with vitamin C in patients with NASH
found no overall improvement in hepatic ﬁbrosis score
compared with placebo [86].
10.2. Anti-cytokine agents
Beneﬁcial eﬀects of anti-TNFa therapies have been
demonstrated in animal models of NASH, and two pilot
studies in patients with NAFLD have reported improve-
ments in aminotransferase levels [87] and histology [88].
Given the emerging importance of pro-inﬂammatory
cytokines in both liver pathology and insulin resistance
in obesity, it seems likely that cytokines and their regu-
latory molecules, including NF-jB, will become major
therapeutic targets in both NAFLD and T2DM in the
near future.
10.3. Ursodeoxycholic acid (UDCA)
Given its long history as a hepatoprotectant and
recent evidence that bile acids may act as molecular
chaperones capable of reducing ER stress implicated
in NASH pathogenesis [56,89] it is hardly surprising that
UDCA has been considered as a potential treatment for
NASH. To date, however, the only large, placebo-con-
trolled RCT in patients with NASH showed no beneﬁt
of UDCA (13–15 mg/kg/day) on liver histology after
2 years’ treatment [90]. More encouraging results have
recently been reported from a study combining UCDA
with vitamin E [91].
10.4. Liver transplantation for patients with NAFLD
Patients with NAFLD who progress to decompensat-
ed cirrhosis or who develop HCC are candidates for
liver transplantation. A favourable outcome depends
on removing the factors that originally caused liver
damage. Perhaps unsurprisingly, steatosis recurs in most
patients within 4 years, with 50% developing NASH and
ﬁbrosis; cases of recurrent cirrhosis are also reported
[92,93]. Risk factors for recurrence are the presence ofinsulin resistance or T2DM pre- and posttransplanta-
tion, weight gain following transplantation, and a high
cumulative steroid dose. These ﬁndings highlight the
importance of ensuring weight and metabolic control
in reducing the risk of disease recurrence, in a group
of patients who will undoubtedly contribute increasing
numbers to transplant programmes in the future.
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